Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
61186372NSC2002
Janssen-Cilag International N.V.
Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
1 trial -
61186372NSC2005
Janssen-Cilag International N.V.
EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
61186372NSC2007
Janssen-Cilag International N.V.
EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
61186372PANSC2001
Janssen-Cilag International N.V.
Unresectable Metastatic Non-small Cell Lung Cancer
1 trial -
61186372PANSC2002
Janssen-Cilag International N.V.
Metastatic Non-small Cell Lung Cancer
1 trial -
67-22 PREcoopERA
Partner Therapeutics Limited
ER-positive/HER2-negative early breast cancer
1 trial -
68Ga-DOTATATE and 68Ga-FAPI
The First People's Hospital of Lianyungang
Tumor Positron-Emission Tomography
1 trial -
68Ga-Dotatoc
Disc Medicine
nasopharyngeal carcinoma
1 trial -
68Ga-FAP-CHX
The First People's Hospital of Lianyungang
Tumor
1 trial -
68Ga-FAPI-46
The George Institute
Triple-negative breast cancer (TNBC) patients at high risk of relapse
1 trial -
68Ga-FAPI-46
Istituto Gentili S.r.l.
oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT
1 trial -
68Ga-FAPI-46
The George Institute
Non-metastatic Pancreatic ductal adenocarcinoma
1 trial -
68Ga-G21
The First People's Hospital of Lianyungang
Prostate Cancer (Adenocarcinoma)
1 trial -
68Ga-NODAGA-SNA006
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cancer
1 trial -
68Ga-NY104 PET/CT
Peking University Third Hospital
Clear Cell Renal Cell Carcinoma
1 trial -
68Ga-NY104 PET/CT
The First People's Hospital of Lianyungang
Clear Cell Renal Cell Carcinoma
1 trial -
6QC-ICG, Placebo for 6QC-ICG
Disc Medicine
Breast cancer
1 trial -
8951-CL-0103
Astellas Pharma GmbH
Advanced cancer of the stomach or the gastroesophageal junction
1 trial -
8951-CL-5201
Astellas Pharma GmbH
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.
1 trial -
89Zr-Girentuximab
Telix Innovations
Clear Cell Renal Cell Carcinoma (ccRCC)
1 trial -
89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
Telix Innovations
Cervical Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Salivary Gland Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Salivary Gland Carcinoma
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Pancreatic Adenocarcinoma
1 trial -
9785-CL-0123
Astellas Pharma GmbH
Prostate Cancer
1 trial -
A Clinical Trial for Patients with Advanced Cancers
Corbus Pharmaceuticals Holdings
Advanced Solid tumour
1 trial -
A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)
Merck Sharp and Dohme
Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)
1 trial -
A study of niraparib in combination with abem... for Ovarian cancer
Fondazione Telethon ETS
Ovarian cancer
1 trial -
A5481092
Pfizer Australia Pty Ltd
recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma
1 trial -
AB-101
Artiva Biotherapeutics
Non Hodgkin Lymphoma
1 trial -
AB-201
Artiva Biotherapeutics
Breast Cancer
1 trial -
AB18001
AB Science
Acute Myeloid Leukemia
1 trial -
AB680
Arcus Biosciences
Metastatic Colorectal Cancer
1 trial -
ABC2
Sana Biotechnology
Breast Cancer
1 trial -
ABC294640
RedHill Biopharma
Cholangiocarcinoma
1 trial -
ABC294640
Apogee Therapeutics
Carcinoma, Hepatocellular
1 trial -
ABC294640
Apogee Therapeutics
Diffuse Large B Cell Lymphoma
1 trial -
ABCSG 45
Shanghai Reinovax Biologics Co.,LTD
Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)
1 trial -
ABCSG 63
Shanghai Reinovax Biologics Co.,LTD
endocrine-responsive HER2-negative early breast cancer
1 trial -
ABEMACICLIB , RO7197597
Fondazione Telethon ETS
ER-positive, HER2-negative Early breast cancer
1 trial -
ABT-C11-2020
Lacuna Pharma Pty Ltd
Metastatic pancreatic ductal adenocarcinoma
1 trial -
ACE-CL-001
Lacuna Pharma Pty Ltd
Richter's Syndrome, Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia
1 trial -
ACE-LY-003
Lacuna Pharma Pty Ltd
Relapsed/Refractory marginal zone lymphoma
1 trial -
ACE-LY-004
Lacuna Pharma Pty Ltd
Mantle Cell Lymphoma
1 trial -
ACR-368
Acrivon Therapeutics
Endometrial Adenocarcinoma
1 trial -
ACR-368-201
Acrivon Therapeutics
Endometrial cancer
1 trial -
ACT16146
Sanofi-aventis Healthcare Pty Ltd
Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.